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Summary 
Background Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves 
cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-
Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 
diabetes that was inadequately controlled by metformin or sulphonylureas. 
Methods 1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a haemoglobin 
A1c (HbA1c) concentration of 6•5-10•0% (mean 7•3% [SD 0•9] at baseline) already on metformin or 
sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and 
randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two 
individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final 
analysis. The primary endpoint was weight change from baseline after 1 year of treatment. Analyses were done 
on an intention-to-treat basis. This trial is registered at ClinicalTrials.gov, number NCT00029848. 
Findings 692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. 
Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: 
-1 · 4 kg [SD 3•6]; 5 mg/day: -2•3 kg [4•2], ρ=0•01 vs placebo; 20 mg/day: -5•3 kg [5•2], ρ<0•0001 vs placebo). 
Rimonabant was generally well tolerated. The incidence of adverse events that led to discontinuation was 
slightly greater in the 20 mg/day rimonabant group, mainly due to depressed mood disorders, nausea, and 
dizziness. 
Interpretation These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can 
produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and 




Type 2 diabetes frequently co-exists with a cluster of other cardiovascular and metabolic risk factors including 
abdominal obesity, low HDL-cholesterol concentrations, high triglyceride concentrations, and raised blood 
pressure,1 and is considered to be a cardiovascular disease risk equivalent.2,3 A recent population-based 
retrospective cohort study showed that diabetes confers an equivalent cardiovascular risk to ageing 15 years in 
people aged 40 years or older.4 The treatment of multiple cardiovascular and metabolic risk factors is central to 
the management of type 2 diabetes.5
Being overweight or obese—in particular, abdominally obese—increases the risk of type 2 diabetes and 
cardiovascular disease,6,7 yet those with diabetes often have more difficulty in losing weight8 and experience 
weight gain associated with most antidiabetic medications.5
The endocannabinoid system, consisting of the cannabinoid type 1 (CBB1) receptor and endogenous lipid-derived 
ligands,  seems to modulate energy homoeostasis as well as glucose and lipid metabolism, both through 9 10-12 
central orexigenic effects and peripheral metabolic effects in adipose tissue, liver, and skeletal muscle.  13-15
Patients with obesity or hyperglycaemia caused by type 2 diabetes exhibit higher concentrations of 
endocannabinoids in visceral fat or serum, respectively, than the corresponding controls.16
In non-diabetic overweight or obese patients, 20 mg daily of the selective CBB1 receptor blocker rimonabant has 
been shown to produce substantial weight loss and waist circumference reduction (a key marker of intra-
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abdominal adiposity), and improvements in multiple cardiovascular and metabolic risk factors.  These data 17,18
were further confirmed in overweight or obese patients with untreated dyslipidaemia.  Part of these metabolic 19
improvements could be attributed to a moderate, but significant, increase in plasma adiponectin levels.19
This multicentre randomised controlled trial was designed to assess the efficacy and safety of rimonabant in 
combination with a mild hypocaloric diet and advice for increased physical activity in overweight or obese 
patients with type 2 diabetes who were already on metformin or sulphonylurea monotherapy. 
Methods  
Patients 
This randomised, double-blind, placebo-controlled study was done in 159 centres in 11 countries (in Europe, 
North America, and South America) between October, 2001, and May, 2004. Patients aged 18-70 years with 
type 2 diabetes who had been treated with metformin or sulphonylurea monotherapy for at least 6 months (stable 
dose for at least 3 months), but who remained inadequately controlled, were recruited. Inclusion criteria were 
body-mass index of 27-40 kg/m2, a haemoglobin A1c (HbA1c) level of 6•5-10•0%, and a fasting glucose 
concentration of 5•55-15•04 mmol/L. Exclusion criteria were unstable bodyweight (defined as more than 5 kg 
variation within the past 3 months), any clinically significant disorder (including severe microvascular or 
macrovascular complications of diabetes), systolic blood pressure greater than 160 mm Hg or diastolic blood 
pressure greater than 95 mm Hg, pregnancy or lactation, recent or planned changes in smoking status, use of 
anti-obesity drugs within the past 3 months, or use of any medication known to affect bodyweight (eg, 
antidepressants). Written informed consent was obtained from all patients. 
The protocol was approved by the Institutional Review Board/Ethics Committee for each centre. The study was 
done in full compliance with the Declaration of Helsinki, with an independent, unblinded data safety monitoring 
board.17-19
Procedures 
The protocol has been described previously17-19 A 2-week screening period preceded a 4-week, placebo run-in 
period, followed by randomisation to double-blind treatment. A randomisation code list, with a block size of 
three, was generated centrally by the sponsor. Treatments were allocated to patients with an interactive voice 
response system in accordance with the predefined randomisation list (1/1/1 ratio for placebo, 5 mg/day 
rimonabant, or 20 mg/day rimonabant, respectively). The interactive voice response system ensured that the 
randomisation of treatment was balanced within all centres and was stratified on the basis of bodyweight loss (≤2 
kg or >2 kg) during the run-in period and class of antidiabetic medication. All patients were put on a mild 
hypocalorific diet and were advised on increased physical activity during the run-in period and until the end of 
the study. 
Standardised assessments of bodyweight, waist circumference, and vital signs were done at screening, twice 
during the run-in period, at baseline (randomisation), and post-randomisation at week 2, week 4, and monthly 
thereafter for 1 year. Glycaemic and lipid variables were measured at screening, baseline, week 12, 24, and 36, 
and at 1 year. Insulin resistance was calculated by use of the homoeostasis model assessment (HOMA-IR).20 The 
diagnosis of metabolic syndrome was assessed in accordance with National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP III) criteria.2
The primary endpoint was weight change from baseline at the last observation carried forward (LOCF). 
Secondary endpoints included changes in HbA1c, HDL cholesterol, triglyceride, fasting glucose, fasting insulin, 
high-sensitivity C-reactive protein (hsCRP), and leptin concentrations, prevalence of metabolic syndrome,2 waist 
circumference, and blood pressure. Measurements of HbA1c, glucose, insulin, total cholesterol, LDL and HDL 
cholesterol, triglyceride, leptin, and hsCRP were done at central laboratories (ICON Laboratories, Farmingdale, 
NY, USA and Dublin, Ireland), together with laboratory safety measurements in accordance with standard 
procedures.17-19 HbA1c was measured by ion exchange high-pressure liquid chromatography (Bio-Rad variant, 
Bio-Rad Laboratories, Hercules, CA, USA) with Diabetes Control and Complications Trial reference values. 
The SF36 health survey questionnaire21 and a patient's satisfaction scale were included in the study as 
exploratory secondary parameters. Patients completed the obesity-specific Impact of Weight on Quality of Life 
(IWQoL-Lite) exploratory secondary questionnaire at baseline and every 3 months for 1 year.22,23 Food 
behaviour was also assessed by a Visual Analog Scale.24 
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Safety assessment was done regularly by an independent data safety and monitoring board and included standard 
adverse event reporting, vital signs, pulse-rate-corrected QT interval, and the Hospital Anxiety and Depression 
(HAD) scale.25
Statistical analysis 
The sample size was calculated on the basis of the assumption that the SD of weight change at year 1 would be 
10 kg. Thus 990 randomised patients (330 patients in every group) would provide 95% confidence to detect a 3 
kg difference between both doses of rimonabant and placebo after 1 year. An α level of 0·025 was chosen to 
ensure an overall type error rate of 0·05 according to a modified Bonferroni procedure. 
Analyses were done on a modified intention-to-treat basis. The modified intention-to-treat population consisted 
of all randomised patients who were exposed to at least one dose of study drug and had at least one post-baseline 
assessment and, when appropriate, a baseline assessment. 
The primary endpoint was analysed with analysis of variance with the modified Bonferroni procedure 
(Hochberg) to adjust for multiple doses.26 The three-way analysis of variance (ANOVA) model included terms 
for treatment and two randomisation strata (weight loss of ≤2 kg or >2 kg during the run-in period and 
antidiabetic therapy with metformin or sulphonylurea); both doses of rimonabant were compared with placebo. 
As an assessment of sensitivity, a post-hoc repeated measures approach was done for changes in weight from 
baseline, because this analysis includes all measurements gathered over time during the study, and thus might 
provide a better assessment in the presence of missing data.27
The repeated measures model included a number of fixed effects (randomisation strata, treatment, number of 
days   from   randomisation,   and   treatment-by-day interaction) and a random effect (the patient). Additionally, 
as another assessment of sensitivity, a more conservative method than LOCF for handling missing data was 
used. For dropouts with post-baseline efficacy, the last value was set to the baseline value—ie, baseline 
observation carried forward (BOCF)—and the change from baseline was set to zero.28 Similar models, excluding 
randomisation strata, were applied to the secondary efficacy parameters. 
Patients were classified as having a response of a 5% or 10% weight loss if they had a reduction in bodyweight 
from baseline at the LOCF of at least 5% or 10%. The incidences of patients who had a weight loss of 5% and 
10% and of those with metabolic syndrome at LOCF were analysed with logistic regression models. The models 
for patients who had weight losses of 5% and 10% included terms for treatment and randomisation strata, and the 
model for the metabolic syndrome included terms for treatment and the status of the metabolic syndrome at 
baseline. 
The effect of rimonabant independent of weight loss was tested with analysis of covariance (ANCOVA) with 
weight loss (change in weight from baseline to 1 year) as a covariate.28 The statistical model for the weight-
adjusted treatment effect is as follows: Y=a+βT+γW+e (ANCOVA model, weight adjusted) where Y is the 
efficacy variable, T is the treatment indicator, and W is weight loss. The weight-independent portion of the total 
treatment effect was calculated as the ratio of the weight-adjusted treatment effect, β, to the treatment effect in 
the overall unadjusted ANOVA model, β1; determined from the ANOVA model: Y=a+β1T+e1.29 This ratio 
indicates the proportion of the total effect size that cannot be explained by weight loss. 
All statistical tests were two-sided; all p values presented are unadjusted. Analyses were done with SAS 
software, version 8.2. 
This trial is registered at ClinicalTrials.gov, number NCT00029848. 
Role of the funding source 
The sponsor participated in discussions regarding study design and protocol development and provided logistical 
support during the trial. Data were gathered by the sponsor and were assessed jointly by the authors and the 
sponsor. Data were interpreted and the manuscript written by the authors, with editorial support provided by the 
sponsor. The corresponding author had full access to all the data and takes responsibility for the integrity of that 
data and the accuracy of the data analysis. The corresponding author had final responsibility for the decision to 
submit for publication. 
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513 men and 532 women were randomised to double-blind treatment. 692 patients (66·2%) completed the 1-year 
follow-up (figure 1). Two randomised patients were not exposed to treatment and 11 randomised patients were 
excluded from the analysis of weight (two for non-exposure and nine for missing post-baseline weight 
assessment). Baseline characteristics were much the same in the three groups (table 1), except smoking, which 
was slightly lower in the 20 mg/day rimonabant group (p=0·02), and fasting triglyceride concentrations, which 
were slightly higher in the 20 mg/day rimonabant group (p=0·03) At screening, mean weight was 96·3 kg (SD 
14·7), mean waist circumference 109 cm (10·8), mean HbA1c 7·3% (0·9), mean fasting plasma glucose 
concentration of 8·3 mmol/L (2·1), and mean prevalence of metabolic syndrome was 79%. Mean reductions in 
weight (-1·5 kg [1·8]), waist circumference (-1·4 cm [3·3]), HbAlc (-0·24% [0·54]), fasting plasma glucose 
concentration (-0·52 mmol/L [1·87]), fasting plasma insulin concentration (-1·1 µlU/mL [10·5]), triglyceride 
concentration (-1·3% [35·3]), HDL-cholesterolconcentration (-1·9% [11·5]), and systolic blood pressure (-2·1 
mm Hg [11·7]) were seen after the placebo run-in. 99·4% (338 of 340), 98·9% (349 of 353), and 99·1% (336 of 
339) of the randomised and exposed patients for whom compliance data were available in the placebo, 5 mg/day, 
and 20 mg/ day groups, respectively, achieved compliance of 80% or more with the study medication. 
Weight loss was significantly greater with both doses of rimonabant than with placebo, independent of age and 
sex (p=0·01 for 5 mg vs placebo, p<0·0001 for 20 mg vs placebo; table 2 and figure 2). The placebo-corrected 
weight loss after 1 year of treatment with 20 mg/day rimonabant was 3·9 kg (SD 0·3); placebo-subtracted losses 
were 4·3 kg (0·4) in patients treated with metformin and 3·1 kg (0·5) in those treated with sulfonylurea after 1 
year of 20 mg/day rimonabant (p<0·0001 for both). The number of patients achieving weight loss of 5% or more 
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and 10% or more at the last follow-up visit was also significantly greater in both groups receiving rimonabant 
than in the placebo group (≥5% loss: p=0·02 for 5 mg and p<0·0001 for 20 mg; ≥10% loss: p=0·01 for 5 mg and 
p<0·0001 for 20 mg; table 2). Waist circumference was significantly lower with both doses of rimonabant than 
with placebo (p=0·02 for 5 mg, p<0·0001 for 20 mg; table 2 and figure 2B). 
Table 1: Characteristics of participants 
Demographics at screening* Placebo group 
(n=348) 
5 mg/day rimonabant group 
(n=358) 
20 mg/day rimonabant 
group (n=339) 
Age (years) 54·8(8·6) 55·9(8·6) 56·0(8·5) 
Sex (% male) 159 (46%) 186 (52%) 168 (50%) 
Race    
   White (%) 308 (89%) 315 (88%) 302 (89%) 
   Black (%) 18 (5%) 20 (6%) 19 (6%) 
Weight (kg) 97·5 (15·1) 98·7(15·1) 97·1 (14·4) 
Waist (cm)    
   Male 114·7 (10·6) 113·6(10·6) 112·9 (10·0) 
   Female 106·5 (10·1) 107·1(10·2) 107·0(10·2) 
Body-mass index (kg/m2) 34·2 (3·6) 34·4(3·6) 34·1(3·6) 
HbA1c(%) 7·5% (0·9) 7·5% (0·8) 7·5% (0·8) 
Current smokers (%) 51 (15%) 43 (12%) 30 (9%) 
Hypertension (%)† 206 (59%) 218(61%) 216 (64%) 
Dyslipidaemia(%)‡ 186 (53%) 202 (56%) 193 (57%) 
Antidiabetic treatment    
    Metformin 230 (66%) 230 (64%) 218 (64%) 
   Sulphonylureas 118 (34%) 128 (36%) 121(36%) 
Efficacy at baseline 
Weight (kg) 96·0(15·1) 97·2 (14·8) 95·7(14·2) 
Waist (cm)    
   Male 113·7 (11·0) 112·0 (10·5) 111·3 (9·6) 
   Female 105·3 (10·6) 106·4(10·1) 106·0(9·9) 
HbA1c(%) 7·2% (0·9) 7·3% (0·8) 7·3% (0·8) 
Fasting glucose (mmol/L) 8·2(2·2) 8·2 (1·8) 8·5(2·2) 
Fasting insulin (µlU/mL) 16·0(13·3) 14·9(9·3) 15·5 (11·3) 
HOMA-IR 5·8 (7·3) 5·3 (3·5) 5·9 (5·0) 
Triglycerides (mmol/L) HDL cholesterol 
(mmol/L) 
1·93 (1·05) 1·95 (1·01) 2·12(1·29) 
   Men 1·06 (0·23) 1·06 (0·22) 1·08 (0·22) 
   Women 1·26(0·28) 1·28(0·28) 1·24(0·28) 
LDL cholesterol (mmol/L) 2·99(0·80) 2·98(0·80) 2·99(0·82) 
Total cholesterol (mmol/L) 5·00(0·96) 499(0·97) 5·06 (0·97) 
Total cholesterol/HDL cholesterol 4·48 (1·17) 4·46(1·20) 4·52 (1·19) 
Non-HDL cholesterol (mmol/L) 3·83(0·92) 3·83(0·2) 3·89(0·95) 
Metabolic syndrome§ 271 (79%) 276 (80%) 267 (79%) 
Supine systolic blood pressure (mm Hg) 128·7(13·1) 130·9 (13·4) 130·3 (12·5) 
Supine diastolic blood pressure (mm Hg) 78·8 (7·8) 79·0(7·9) 79·0(7·8) 
hsCRP (mg/L) 6·3 (8·1) 5·9 (7·3) 5·4(6·5) 
Leptin (ng/mL) 16 (8·7) 16(9·3) 16(9·1) 
Safety at baseline 
Heart rate (bpm) 67·0 (10·3) 64·8(9·8) 68·5 (10·6) 
QTcF (ms)¶ 406·0 (19·1) 406·0 (21·1) 407·4 (18·1) 
HAD/depression|| 3·1(2·8) 2·8(2·6) 3·1(2·9) 
HAD/anxiety|| 5·2 (3·4) 4·9(3·2) 5·1(3·6) 
Data are number (%) or mean (SD). *Screening data split into treatment groups retrospectively after randomisation, † Defined as systolic 
blood pressure ≥130 mm Hg or supine diastolic blood pressure ≥85 mm Hg, or both; overall 93% of patients with hypertension were treated. 
‡Defined for men as LDL-cholesterol concentration ≥3·36 mmol/L, or H DL-cholesterol concentration <1·03 mmol/L for men and <1·3 
mmol/L for women, or triglyceride concentration ≥1·69 mmol/L; overall 65% of patients with dyslipidaemia were treated. §Patients had 
metabolic syndrome as detected according to NCEP-ATP III.2 Data on metabolic syndrome at baseline available for 342,347, and 337 
patients in the placebo, 5 mg, and 20 mg groups, respectively. ¶QT interval corrected for heart rate. ||HAD=Hospital Anxiety and Depression. 
The HAD scale consists of 14 items measuring the level of anxiety and depression in two separate subscales. Scale scores range from 0 (no 
symptoms) to 21 (maximum distress) for both depression and anxiety and is interpreted with the following cut points: 0-7= normal, 8-
10=mild disturbance (probable case), ≥11=moderate to mood disturbance (definite case). 
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Table 2: Changes in weight and risk factors 





(5 mg υs 
placebo) 
p value 
(20 mg υs 
placebo) 
Number of patients with data at last visit 345 355 336   
Change from baseline (kg) -14(3·6) -2·3 (4·2) -5·3 (5·2) 0·01 <0·0001 
 ≥5% weight loss 50 (14·5%) 77 (21·7%) 166 (49·4%) 0·02 <0·0001 
≥10% weight loss 7(2·0%) 22(6·2%) 55 (16·4%) 0·01 <0·0001 
Waist circumference 
Number of patients with data at last visit 344 355 336   
Change from baseline (cm) -1·9 (5·5) -2·9(5·6) -5·2 (6·1) 0·02 <0·0001 
HbA1c      
Number of patients with data at last visit 317 330 315   
Change from baseline (%) 0·1% (1·0) -0·1% (1·0) -0·6% (0·8) 0·03 <0·0001 
Patients that achieved HbA1c <6·5% 66 (21%) 78 (24%) 135 (43%) 0·39 <0·0001 
Patients that achieved HbA1c<7% 151 (48%) 168 (51%) 214 (68%) 0·40 <0·0001 
Change from baseline in patients taking 
metformin* (%) 
0·1% (1·0) -0·1% (1·1) -0·6% (0·8) 0·19 <0·0001 
Change from baseline in patients taking 
sulphonylureas† (%) 
0·1% (1·1) -0·1% (0·9) -0·5% (0·8) 0·07 <0·0001 
Fasting glucose concentration 
Number of patients with data at last visit 317 331 317   
Change from baseline (mmol/L) 0·33(2·32) 0·30(2·06) -0·64(1·96) 0·86 <0·0001 
Fasting insulin 
Number of patients with data at last visit 314 328 311   
Change from baseline (µlU/mL) 0·4(14·8) 0·7(9·0) -0·7(9·9) 0·76 0·25 
HOMA-IR 
Number of patients with data at last visit 308 319 309   
Change from baseline 0·6(8·9) 0·6(4·2) -0·5 (5·7) 0·97 0·03 
HDL cholesterol‡ 
Number of patients with data at last visit 314 331 318   
Change from baseline (mmol/L) 0·07 (0·15) 0·11 (0·19) 0·17(0·20) 0·02 <0·0001 
Change from baseline (%) 7·1% (13·5) 9·2% (15·8) 15·4% (17·4) 0·08 <0·0001 
Triglycerides‡ 
Number of patients with data at last visit 314 330 317   
Change from baseline (mmol/L) 0·04(0·87) -0·01 (0·79) -0·35 (1·28) 0·50 <0·0001 
Change from baseline (%) 7·3% (43·0) 1·3% (35·1) -9·1% (44·3) 0·07 <0·0001 
Total cholesterol/HDL cholesterol ratio 
Number of patients with data at last visit 314 330 317   
Change from baseline -0·16 (0·79) -0·23 (0·80) -0·51(0·82) 0·27 <0·0001 
Change in non-HDL cholesterol‡ 
Number of patients with data at last visit 314 330 317   
Change from baseline (mmol/L) 0·02 (0·85) 0·00 (0·75) -0·13(0·80) 0·70 0·02 
Change from baseline (%) 2·5% (22·5) 2·0% (21·1) -1·8% (21·0) 0·75 0·01 
Total cholesterol‡ 
Number of patients with data at last visit 314 331 317   
Change from baseline (mmol/L) 0·10(0·88) 0·11 (0·76) 0·04(0·82) 0·90 0·36 
Change from baseline (%) 3·3% (17·7) 3·3% (16·2) 2·0% (16·5) 0·98 0·32 
LDL cholesterol‡ 
Number of patients with data at last visit 314 331 317   
Change from baseline (mmol/L) 0·13 (0·76) 0·13 (0·66) 0·09 (0·79) 0·99 0·52 
Change from baseline (%) 7·2% (26·3) 7·5% (26·8) 6·9% (34·5) 0·89 0·90 
Metabolic syndrome 
Number of patients with data at last visit 316 331 318   
Improvement at 1 year 44/251 (18%) 57/260(22%) 66/252(26%) 0·21 0·02 
Development at 1 year 25/65 (38%) 21/71 (30%) 18/66 (27%) 0·28 0·17 
Supine systolic blood pressure 
Number of patients with data at last visit 345 355 336   
Change from baseline (mm Hg) 1·6(13·2) -0·4(12·9) -0·8(12·8) 0·04 0·02 
Supine diastolic blood pressure 
Number of patients with data at last visit 345 355 336   
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Change from baseline (mm Hg) -0·7 (8·4) -0·4(8·5) -1·9(8·2) 0·70 0·06 
hsCRP 
Number of patients with data at last visit 308 323 313   
Change from baseline (mg/L) -0·0 (10·0) -0·5 (5·8) -1·4(5·2) 0·48 0·02 
Leptin 
Number of patients with data at last visit 290 308 294   
Change from baseline (ng/mL) 3·1 (7·5) 1·9 (6·1) -0·3 (6·0) 0·03 <0·0001 
Data are mean (SD) or n/N (%), unless otherwise indicated. HOMA-IR=Homoeostasis Model of Assessment of insulin resistance. *n=211, 
n=209, and n=204 in the placebo, 5 mg/day, and 20 mg/day rimonabant groups, respectively, at the end of study. †n=106, n=121, n=111 in 
the placebo, 5 mg/day, and 20 mg/day rimonabant groups, respectively, at the end of study. ‡Analyses of cholesterol (total, LDL, HDL, and 
non-HDL) and triglycerides were done on percent changes from baseline. 
 
HbAlc levels were lower with both doses of rimonabant than with placebo (p=0·03 for 5 mg and p<0·0001 for 20 
mg; table 2 and figure 3A and B) with a sustained decline in the 20 mg/day rimonabant group (figure 3A). 
Treatment with metformin or sulphonylurea did not affect HbAlc levels (table 2). More patients in the 20 mg/day 
rimonabant group reached an HbAlc target of less than 6·5%30 and less than 7%31 than did those in the placebo 
group (p<0·0001 for both target levels; table 2). The observed effects of 20 mg/day rimonabant on Hb Alc were 
about twice that attributable to concurrent weight loss alone after adjustment with ANCOVA (figure 3C). For 
example, of the observed placebo-subtracted 0·7% reduction in HbAlc with 20 mg/day rimonabant, 0·4% (SD 
0·1) remained after weight-loss adjustment, equivalent to 57% (10) of the overall response (p<0·0001). In the 20 
mg/day rimonabant group more patients needed downward adjustment of their antidiabetic medication than did 
those in the placebo group (table 3). 
Improvements in fasting glucose concentrations and HOMA-IR were greater in the 20 mg/day rimonabant group 
than in the placebo group (p<0·0001 and p=0·03, respectively; table 2). HDL cholesterol, triglyceride, and non-
HDL-cholesterol concentrations also improved more with 20 mg/day rimonabant than with placebo (p<0·0001 
for all; table 2 and figure 2C and D). The residual effect on HDL-cholesterol concentration of 20 mg/day 
rimonabant was 57% (14) of the observed effect after adjustment for weight loss (ρ<0·0001). The residual effect 
on triglyceride concentration after adjustment for weight loss was 36% (20) of the observed effect, which was 
not significant (p=0·08). The persisting prevalence of the metabolic syndrome was lower in the 20 mg/day 
rimonabant group than in the placebo group at 1 year (p=0·02; table 2). Supine systolic blood pressure was lower 
in both rimonabant groups than it was in the placebo group (p=0·04 for 5 mg, p=0·02 for 20 mg; table 2). 
However, the residual effect on supine systolic blood pressure after adjustment for weight loss was 48% (42) of 
the observed effect, which was not significant (p=0·30). The prevalence of hypertension in the 20 mg/day 
rimonabant group was much the same as that in the placebo group and it did not differ between baseline and 1 
year of treatment (54·8% vs 53·9%, respectively, in the 20 mg/day group). The decrease in hsCRP levels was 
greater in the 20 mg/day rimonabant group than it was in the placebo group (p=0·02; table 2). Change in 
fibrinogen concentrations were much the same in all three groups (data not shown). Leptin levels—a marker of 
fat mass— were lower in the 20 mg/day rimonabant group than they were in the placebo group (p<0·0001; table 
2). 
Improvements were seen for all food behaviour parameters in the 20 mg/day rimonabant group at 1 year. Patients 
in the 20 mg/day rimonabant group reported less appetite (p<0·0001), easier to follow the diet (p<0·0001), less 
desire for high fat foods (p=0·0003), and less desire for sweets (p=0·04) than did those in the placebo group (data 
not shown). A number of exploratory secondary parameters were investigated as per protocol. A greater 
improvement in physical functioning (as assessed by SF36; p=0·012; data not shown) and a greater impairment 
in mental health score (p=0·022) were recorded at 1 year in the 20 mg/ day rimonabant group than in the placebo 
group (data not shown). Furthermore, more patients on 20 mg/day rimonabant reported being "very" or 
"exceptionally" satisfied at 1 year than did patients on placebo (p=0·001), as assessed by a patient's satisfaction 
scale (data not shown). Health-related quality of life was specifically assessed with IWQoL-Lite. A greater 
improvement at 1 year in the physical function (p=0·002) and self-esteem domains (p=0·004) and in the total 
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Figure 2: Changes in weight, waist, HDL cholesterol, and triglycerides (A) Mean (SE) change from baseline in 
bodyweight over 1 year; last observation carried forward (LOCF), baseline observation carried forward (BOCF), and repeated measures 
(RM), *p<0·001, †p=0·01, ‡p=0·03 vs placebo. (B) Mean (SE) change from baseline in waist circumference over 1 year; LOCF, BOCF, and 
RM. *p<0·001, †p=0·02, ‡p=0·03 vs placebo. (C) Mean (SE) percentage change from baseline in HDL-cholesterol concentration over 1 
year; LOCF, BOCF, and RM. *p<0·001, †p=0·05 vs placebo. (D) Mean (SE) percentage change from baseline in triglyceride levels over 1 
year; LOCF, BOCF, and RM. *p<0·001 vs placebo. 
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Figure 3: Changes in HbA1c levels (A) Mean (SE) change from baseline in HbA1c levels over 1 year. (B) Mean (SE) change from 
baseline in HbAlc levels: last observation carried forward (LOCF), baseline observation carried forward (BOCF), and repeated measures 
(RM) *p<0·0001, †p=0·03, ‡p=0·04, §p=0·05 vs placebo. (C) Linear regression analysis between HbA1c changes and bodyweight changes, 
excluding patients with extreme weight loss (≥11·2 kg), in patients receiving placebo or 20 mg/day rimonabant. The weight change data from 
lowest to highest was divided into ten groups with about equal sample size (deciles) and within each decile the mean weight change and the 
mean change in HbA1c was calculated The pairs of mean changes (weight, HbAlc) were plotted along with the regression line to illustrate the 
relation between weight loss and HbAlc. 
 
 
A slightly greater proportion of patients in the rimonabant treatment groups experienced adverse events than did 
those in the placebo group (table 4). The most common adverse events, occurring in 5% or more rimonabant-
treated patients, were nausea, diarrhoea, vomiting, dizziness, hypoglycaemia, fatigue, and anxiety (table 4); these 
were generally mild or moderate, transient and self-limited, and seen early in the treatment period. In the 20 
mg/day rimonabant group, hypoglycaemia was reported more frequently in diabetic patients treated with 
sulphonylureas than in those given metformin, but only one case led to treatment discontinuation. 
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Although overall discontinuation rates were much the same in all groups, discontinuations due to adverse events 
were more frequent in the 20 mg/day and 5 mg/day rimonabant groups than they were in the placebo group 
(table 4). Dropouts due to adverse events in the 20 mg/ day group were much the same in patients who lost 
weight (-5 kg or more) as in those who gained weight (≥0 kg)-10·6% (16 of 151 patients) and 12·8% (5 of 39 
patients), respectively. The most common adverse events that led to premature study discontinuation in the 20 
mg/day rimonabant group were depressed mood disorders, nausea, and dizziness (table 4). However, no serious 
adverse events linked to psychiatric disorders were recorded in either rimonabant group. 
Cardiovascular safety endpoint measures and HAD depression and anxiety subscores were much the same across 
the three treatment arms at baseline and at 1 year (table 1 and table 4). Although there was a trend towards slight 
increases in both HAD scores in the 20 mg/day rimonabant group compared with the placebo group, the 
observed increases should be considered to be marginal. 
 
Discussion 
The main finding of the RIO-Diabetes trial is that 20 mg/day rimonabant for 1 year significantly reduced weight, 
waist circumference, and HbAlc levels and improved a number of cardiovascular and metabolic risk factors in 
overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or 
sulphonylurea. These results extend previous findings in non-diabetic overweight or obese patients to those with 
type 2 diabetes.17-19 Patients with type 2 diabetes are characterised by resistance to weight loss,8 overactivity of 
the endocannabinoid system,16 and increased cardiovascular risk,2,3 with obesity being deemed to be an 
additional and independent risk factor.32
Treatment with 20 mg/day rimonabant enabled a greater number of patients on monotherapy with metformin or 
sulphonylurea whose baseline HbAlc levels were close to the American Diabetes Association recommended level 
(7%) to attain such a target.31 The placebo-corrected reduction in HbAlc levels of 0·7% seen with 20 mg/day 
rimonabant is clinically relevant, since every 1% reduction in HbAlc has been shown to be associated with a 
reduction in risk of 21% for any endpoint related to diabetes.33 For the purpose of comparison, in metformin-
treated diabetic patients, treatment with twice-daily subcutaneous injection of 10 µg exenatide induced a 0·86% 
placebo-subtracted reduction in HbAlc after 30 weeks, a decrease that is close to that recorded with 20 mg/day 
rimonabant with baseline HbAlc levels above 8%.34 
Improved glycaemic control has an important beneficial effect on the risk of microvascular and macrovascular 
complications related to diabetes.33 Nevertheless, in recent years considerable emphasis has been placed on 
aggressive management of multiple cardiovascular and metabolic risk factors in type 2 diabetes patients.35,36 20 
mg/day rimonabant improved atherogenic dyslipidaemia and diminished systolic blood pressure in diabetic 
patients, and also reduced the prevalence of metabolic syndrome,37 as already reported in overweight 
dyslipidaemic non-diabetic patients.19 Compared with placebo, 20 mg/day rimonabant also reduced hsCRP 
levels, an inflammatory biomarker considered to be a moderate predictor of cardiovascular disease.38
 









No change 268 (77·7%) 279(78·6%) 255 (75·9%) 
Increase 44 (12·8%) 49(13·8%) 38 (11·3%) 
Decrease 26 (7·5%) 22(6·2%) 40(11·9%) 
Another drug added due to insufficient efficacy 7(2.0%) 3(0·8%) 0 (0%) 
Another drug added due to other reasons 0 (0%) 2(0·6%) 3 (0·9%) 
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Table 4: Safety data at 1 year and adverse events in randomised and exposed patients 
 Placebo (n=348) 5 mg/day 
rimonabant 
(n=358) 
20 mg/day rimonabant 
(n=339) 
Safety data at 1 year 
Overall dropout rate 117 (34%) 126 (35%) 110 (32%) 
Patients with any adverse event 276 (79%) 293 (82%) 288 (85%) 
Patients with any serious adverse event* 15 (4%) 27(8%) 27(8%) 
Discontinuations dueto adverse events 19 (5%) 28 (8%) 51 (15%) 
Adverse events that led to study discontinuation† 
Psychiatric disorders    
   Depressed mood disorders‡ 3(0·9%) 0 11 (3%) 
   Anxiety 0 0 2 (0·6%) 
   Aggression 0 2(0·6%) 0 
Nervous system disorders    
   Headache  1 (0·3%) 1 (0·3%) 2 (0·6%) 
   Dizziness 0 0 3 (0·9%) 
   Paraesthesia 0 0 2 (0·6%) 
Gastrointestinal disorders    
   Nausea 1 (0·3%) 0 5 (1·5%) 
   Vomiting 0 0 2 (0·6%) 
General disorders    
   Chest pain 0 0 2 (0·6%) 
   Asthenia/fatigue 0 2(0·6%) 1 (0·3%) 
Adverse events with an incidence of >5% in any group 
Nausea 20 (6%) 22(6%) 41 (12%) 
Nasopharyngitis 74 (21%) 59 (16%) 41 (12%) 
Dizziness 17(5%) 11 (3%) 31 (9%) 
Arthralgia 28 (8%) 35 (10%) 30 (9%) 
Headache 32 (9%) 29 (8%) 28 (8%) 
Diarrhoea 23(7%) 22(6%) 25 (7%) 
Back pain 24(7%) 22(6%) 24(7%) 
Upper respiratory tract infection 33 (9%) 28 (8%) 23 (7%) 
Vomiting 8(2%) 14 (4%) 20 (6%) 
Hypoglycaemia 6(2%) 5(1%) 18 (5%) 
Fatigue 13 (4%) 19 (5%) 18 (5%) 
Anxiety 9(3%) 4(1%) 17(5%) 
Safety endpoints 
Heart rate (bpm)‡   314 
   Number of patients with data at last visit 314 332  
   Year 1 67·8 (10·8) 69·3 (10·1) 69·5 (11·4) 
   Change from baseline  0·8(8·8) 0·9(8·7) 1·0(10·2) 
QTcF (ms)‡    
   Number of patients with data at last visit 313 331 314 
   Last recorded value 403·9 (20·1) 404·4(19·8) 407·1 (19·4) 
   Change from baseline  -2·1(16·6) -1·6(16·3) -0·3(15·4) 
HAD/depression‡    
   Number of patients with data at last visit 279 286 262 
   Last recorded value 2·9 (3·0) 2·7(2·8) 3·3(3·3) 
   Change from baseline  -0·2 (2·6) -0·1 (2·3) 0·3(2·9) 
HAD/anxiety‡    
   Number of patients with data at last visit 279 285 262 
   Last recorded value 4·9 (3·6) 4·7(3·6) 5·5 (4·0) 
   Change from baseline -0·3 (3·2) -0·1 (2·7) 0·4(3·4) 
Data are number (%) or mean (SD), unless otherwise indicated.*There was one death during the placebo run-in period (cardiac arrest) and 
four deaths during the double-blind treatment period. One patient in the 5 mg/day rimonabant group died of septic shock 6 months after 
starting the study treatment, while in the 20 mg/day rimonabant group, one patient was a passenger in a traffic accident (more than 6 months 
after the start of study treatment) and two metformin-treated patients with multiple risk factors died of a cardiovascular disease (one death 2 
months and the other 5 months after the start of study treatment). No causal relation to the study drug was suspected by the investigators for 
any death. In the overall RIO trial programme (n=6625; four studies), deaths were equally distributed across groups (four in the placebo 
group, three in the 5 mg/day rimonabant group, and four in the 20 mg/day rimonabant group), † According to MedDRA, in at least two 
patients in any rimonabant group and in main system organ class (≥1%). One patient can report several events. ‡Depressed mood disorders 
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corresponded to the MedDRA HLGT term "Depressed mood disorders and disturbances" and consist of depression, major depression, 
depressed mood, and depressive symptoms. 
 
57% of placebo-subtracted effects of 20 mg/day rimonabant on HDL-cholesterol concentrations and HbAlc levels 
were independent of weight loss, consistent with the direct peripheral metabolic effects of the drug.13,15,17,18,39 
Rimonabant increases the secretion of adiponectin,19 an adipokine whose plasma concentrations correlates 
positively with insulin sensitivity, and levels of which are lower both in obese and type 2 diabetic patients than 
in lean healthy individuals.40 Although low adiponectin levels have been deemed to be a predictor of 
cardiovascular disease, further studies are needed to confirm this association.41 The blockade of CBB1 receptors 
might also inhibit hepatic fatty acid synthesis and hepatic lipid accumulation, which have also been implicated in 
insulin resistance and dyslipidaemia.14
Intentional weight loss in overweight or obese type 2 diabetes patients improves lipid profile, blood pressure, 
and diabetes control.5 Weight loss has been shown to be associated with a reduced mortality risk in observational 
studies,42 although such an association has not been recorded in randomised clinical trials yet. Although only 
moderate weight loss (5-10% of bodyweight) is required to improve glycaemic control, weight loss and 
maintenance of weight loss in patients with type 2 diabetes are generally more difficult than in non-diabetic 
individuals.8,43 Furthermore, most antidiabetic medications (in particular sulphonylureas, thiazolidinediones, and 
insulin) produce concomitant weight gain.5,31,44 In this study, a mean weight loss of 6·1 kg was noted in patients 
who completed the 1-year treatment with 20 mg/day rimonabant, much the same as that described in the 
Diabetes Prevention Program (DPP),45 in which patients were treated with an intensive lifestyle intervention. 
However, lifestyle intervention in the DPP was highly demanding and applied to non-diabetic individuals, a 
population that has less difficulty in losing weight than diabetic patients.8 In a study done on 114 obese patients 
with type 2 diabetes submitted to a 12-month follow-up after a 10-16-week behavioural weight-control 
programme, only 27 patients (24%) who succeeded in obtaining a prolonged weight reduction above 6-9 kg 
exhibited a significant reduction in HbAlc levels after 1 year.46 The authors of a recent consensus statement 
recognised that for most individuals with type 2 diabetes, lifestyle interventions fail to achieve or maintain 
metabolic goals, either because of failure to lose weight, weight regain, progressive disease, or a combination of 
factors.47
In agreement with previous data,8 the placebo-subtracted weight loss at 1 year of treatment with 20 mg/day 
rimonabant was 3·9 kg in the present study in patients with diabetes compared with 4·7 kg and 5·4 kg reported in 
patients without diabetes.17-19 Due to its unique mode of action and because of the absence of head-to-head trials, 
comparison of the results obtained with 20 mg/day rimonabant with those reported with orlistat or sibutramine 
should be cautious. Nevertheless, this study shows greater weight loss and HbAlc reduction than those reported in 
a recent meta-analysis of sibutramine or orlistat trials in patients with type 2 diabetes and similar demographic 
characteristics (ie, age, sex, and body-mass index), but higher baseline HbAlc levels (9·1-9·3% instead of 7·3% in 
RIO-Diabetes).48
20 mg/day rimonabant improved health-related quality of life, especially physical functioning, which points to a 
positive effect of the drug on this health-related concept.21 Rimonabant was well tolerated in this study, with 
adverse events that were generally transient and mild, and much the same as the safety profile reported in non-
diabetic patients.17-19 The most frequent adverse event that led to premature withdrawal in the 20 mg/day 
rimonabant group was the occurrence of self-reported depression. However, objective measures of depression 
and anxiety from the HAD scales25 showed only slight and probably not clinically relevant changes in the 20 
mg/day rimonabant group compared with the placebo group. Nevertheless, in this trial, as in other RIO-trials,17-19 
patients with severe psychiatric disorders or receiving antidepressants were excluded, so the safety of rimonabant 
in such individuals remains to be determined. 
There are two limitations to our study. First, although consistent with that of previous 1-year studies in 
overweight or obese patients,49 including those done in patients with type 2 diabetes,48 the retention rate of about 
66% in all treatment groups might be considered as rather low. One should note that the dropout rate in this 
study was lower than in previously reported studies with rimonabant in non-diabetic patients.17-19 The 
discontinuation due to reasons other than adverse events was about threefold higher in patients who gained 
weight than in those who lost weight; this difference was noted in all three treatment arms. Nevertheless, 
dropouts due to adverse events in the 20 mg/day rimonabant group was much the same in patients who lost 
weight as in those who gained weight. To take into account the dropout rate, two additional sensitivity analyses, 
including a repeated measures approach and a BOCF approach, were done, and the results supported the 
conclusions of the LOCF analysis (figure 2). Second, RIO-Diabetes is a 1-year trial and long-term studies will be 
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needed to assess the effect on diabetes-related complications, especially cardiovascular outcomes. 
The results of RIO-Diabetes show the therapeutic value of 20 mg/day rimonabant in patients with type 2 diabetes 
through effective weight loss, reduced abdominal adiposity, a clinically significant reduction in HbAlc levels, and 
improvements in HDL-cholesterol, triglyceride, and hsCRP concentrations, and systolic blood pressure. The 
improvements in HbAlc and HDL-cholesterol concentration levels were twice that expected from the weight loss 
alone, consistent with the direct peripheral metabolic effects of the drug. These findings support the use of 20 
mg/day rimonabant, in addition to diet and exercise, as a new approach to improve glucose control and reduce a 
number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes that is 
inadequately controlled with metformin or sulphonylureas. 
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